Profile data is unavailable for this security.
About the company
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
- Revenue in USD (TTM)207.11m
- Net income in USD-50.35m
- Incorporated2009
- Employees300.00
- LocationAurinia Pharmaceuticals Inc#140, 14315 - 118 AVENUEVICTORIA T5L 4S6CanadaCAN
- Phone+1 (250) 744-2487
- Fax+1 (604) 369-4115
- Websitehttps://www.auriniapharma.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oruka Therapeutics Inc | 0.00 | -7.20m | 891.41m | 4.00 | -- | 0.9453 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
Zymeworks Inc | 62.71m | -112.51m | 893.07m | 290.00 | -- | 2.21 | -- | 14.24 | -1.52 | -1.52 | 0.8531 | 5.69 | 0.1122 | -- | 1.55 | 230,533.10 | -20.13 | -22.58 | -23.21 | -26.90 | -- | -- | -179.42 | -91.17 | -- | -- | 0.00008 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
Perspective Therapeutics Inc | -1.87m | -49.02m | 900.16m | 116.00 | -- | 2.64 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
Prothena Corporation PLC | 217.25m | -50.92m | 906.74m | 173.00 | -- | 1.56 | -- | 4.17 | -1.01 | -1.01 | 3.94 | 10.82 | 0.318 | -- | 829.18 | 1,255,757.00 | -7.45 | -14.20 | -8.16 | -15.11 | -- | -- | -23.44 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
IGM Biosciences Inc | 2.91m | -220.40m | 914.10m | 204.00 | -- | 7.46 | -- | 314.02 | -3.67 | -3.67 | 0.0485 | 2.07 | 0.0071 | -- | -- | 12,995.54 | -53.94 | -44.66 | -59.96 | -48.20 | -- | -- | -7,571.35 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
Arrivent Biopharma Inc | 0.00 | -74.89m | 915.55m | 40.00 | -- | 3.08 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
Sana Biotechnology Inc | 0.00 | -244.90m | 941.03m | 328.00 | -- | 2.77 | -- | -- | -1.15 | -1.15 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -36.94 | -38.99 | -42.11 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Cullinan Therapeutics Inc | 0.00 | -142.16m | 947.34m | 85.00 | -- | 1.44 | -- | -- | -3.10 | -3.10 | 0.00 | 11.34 | 0.00 | -- | -- | 0.00 | -23.96 | -12.37 | -24.85 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Pharvaris NV | 0.00 | -125.23m | 982.94m | 82.00 | -- | 2.69 | -- | -- | -2.62 | -2.62 | 0.00 | 6.76 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
Aurinia Pharmaceuticals Inc | 207.11m | -50.35m | 1.02bn | 300.00 | -- | 2.79 | -- | 4.92 | -0.3508 | -0.3508 | 1.44 | 2.55 | 0.3862 | 0.8006 | 9.20 | 690,350.00 | -9.39 | -25.97 | -10.78 | -28.24 | 86.08 | -- | -24.31 | -137.64 | 4.82 | -- | 0.1778 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
AnaptysBio Inc | 30.47m | -170.12m | 1.03bn | 117.00 | -- | 94.36 | -- | 33.66 | -6.34 | -6.34 | 1.14 | 0.3601 | 0.0645 | -- | 5.00 | 260,453.00 | -36.02 | -18.08 | -39.45 | -18.96 | -- | -- | -558.25 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
Phathom Pharmaceuticals Inc | 9.92m | -297.11m | 1.03bn | 452.00 | -- | -- | -- | 103.65 | -5.13 | -5.13 | 0.1717 | -3.99 | 0.0339 | 1.72 | -- | 21,942.48 | -101.68 | -83.26 | -115.19 | -93.77 | 80.15 | -- | -2,995.68 | -135,982.00 | 6.44 | -5.74 | 1.86 | -- | -- | -- | -1.96 | -- | -- | -- |
Relay Therapeutics Inc | 35.21m | -322.83m | 1.06bn | 304.00 | -- | 1.28 | -- | 30.03 | -2.52 | -2.52 | 0.277 | 5.11 | 0.0406 | -- | -- | 109,003.10 | -37.22 | -28.55 | -39.91 | -29.54 | -- | -- | -916.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
Vir Biotechnology Inc | 78.88m | -483.04m | 1.06bn | 587.00 | -- | 0.7374 | -- | 13.41 | -3.58 | -3.58 | 0.5838 | 10.50 | 0.0403 | -- | -- | 134,373.10 | -24.69 | -0.6081 | -26.90 | -0.7192 | 98.80 | -- | -612.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Dec 2023 | 9.54m | 6.67% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 8.92m | 6.24% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.77m | 1.94% |
Tang Capital Management LLCas of 31 Mar 2024 | 2.05m | 1.43% |
Goldman Sachs Asset Management LPas of 31 Mar 2024 | 1.83m | 1.28% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.76m | 1.23% |
The Vanguard Group, Inc.as of 05 Jul 2024 | 1.42m | 0.99% |
Teachers Advisors LLCas of 30 Jun 2024 | 1.17m | 0.82% |
Rock Springs Capital Management LPas of 31 Mar 2024 | 1.15m | 0.80% |
Schroder Investment Management Ltd.as of 31 Mar 2024 | 1.04m | 0.73% |